When you work with us on weight loss, whether youre using GLP-1 medications or not, you dont just lose weight
CagriSema combines semaglutide with the amylin analogue cagrilintide, engaging anatomically distinct CNS satiety pathways (Phase 3)
Wegovy oral (semaglutide pill) , FDA-approved for weight loss in late 2025 and launched January 2026, runs $189$299/mo through manufacturer direct programs and select telehealth routes
CJC-1295 + Ipamorelin is a research peptide blend combining a DAC-modified GHRH analogue (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin)
If youre on a weight loss journey, you now have an arsenal of medications at your disposal
Brand reputation: Choose products from providers that can guarantee third-party testing, proper formulation standards, and clinical support